✦ LIBER ✦

713 ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS WITHOUT PRIOR CHEMOTHERAPY - INTERIM ANALYSIS OF THE COU-AA-302 PHASE 3 TRIAL

✍ Scribed by Saad, Fred; Shore, Neal D; Van Poppel, Hendrik; Rathkopf, Dana; Smith, Matthew R.; de Bono, Johann S.; Logothetis, Christopher; de Souza, Paul; Fizazi, Karim; Mulders, Peter FA; Mainwaring, Paul; Hainsworth, John D; Beer, Tomasz M; North, Scott; Fradet, Yves; Griffin, Tom; Kheoh, Thian; Small, Eric J; Scher, Howard I; Molina, Arturo; Ryan, Charles J

Book ID: 122451892
Publisher: Lippincott Williams and Wilkins
Year: 2013
Tongue: English
Weight: 51 KB
Volume: 189
Category: Article
ISSN: 0022-5347
DOI: 10.1016/j.juro.2013.02.272

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Updated Interim Efficacy Analysis and Lo

Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)

✍ Rathkopf, Dana E.; Smith, Matthew R.; de Bono, Johann S.; Logothetis, Christophe 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 987 KB

97 Updated interim analysis (IA): Result

97 Updated interim analysis (IA): Results of randomized phase 3 study COU-AA-302 of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy

✍ Van Poppel, H.; Rathkopf, D.; Smith, M.R.; De Bono, J.S.; Logothetis, C.J.; Shor 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 109 KB

MP70-11 IMPACT OF PRIOR ENDOCRINE THERAP

MP70-11 IMPACT OF PRIOR ENDOCRINE THERAPY ON CLINICAL BENEFIT OF ABIRATERONE ACETATE IN PATIENTS WITH CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: RESULTS FROM COU-AA-302

✍ Saad, Fred; Kheoh, Thian; Yu, Margaret K.; Smith, Matthew R.; Small, Eric J.; Mu 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 146 KB

PD27-01 EFFICACY AND LONG-TERM SAFETY AN

PD27-01 EFFICACY AND LONG-TERM SAFETY ANALYSIS OF STUDY COU-AA-302: ABIRATERONE ACETATE PLUS PREDNISONE IN CHEMOTHERAPY-NAÏVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

✍ Shore, Neal; Rathkopf, Dana; Smith, Matthew R.; de Bono, Johann S.; Logothetis, 📂 Article 📅 2014 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 509 KB

105 Exploratory analysis of the visceral

105 Exploratory analysis of the visceral disease patient subset in COU-AA-301, a phase III study of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer (mCRPC)

✍ Suttmann, H.; Mulders, P.F.A.; Molina, A.; Goodman, O.B.; Flaig, T.W.; Li, J.; K 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 74 KB

7001 ORAL Abiraterone Acetate Improves F

7001 ORAL Abiraterone Acetate Improves Functional Status in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Post-docetaxel – Results From the COU-AA-301 Phase 3 Study

✍ Harland, S.; de Bono, J.S.; Haqq, C.M.; Staffurth, J.N.; Hao, Y.; Gagnon, D.; Li 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 41 KB